Topic: ulcerative colitis

Ferring sees the deal as an R&D acquisition that will keep delivering beyond the "front-runner project."

The oral alpha-4-beta-7 integrin antagonist performed badly enough in the first 65 patients for a committee to rule it would be futile to continue.

Topline data show that Arena's ulcerative colitis candidate, etrasimod, beat out placebo in phase 2.

If successful in further trials, OPRX-106 could mount a challenge in the market for injectable and infused TNF drugs.

Theravance will bring its GI drug through phase 2/3 in Crohn's disease and ulcerative colitis.

Galapagos has taken up its option to co-promote filgotinib with Gilead in certain European nations, but Gilead will be free to acquire its partner in two weeks.

Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.

The microbiome pioneer thinks the data support the rapid advance of SER-287 deeper into the clinic, although question marks about the results remain.

After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.

The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.